Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	39.41B
Revenue (ttm)	25.44B
Net Income (ttm)	190.49M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	206.90
Forward PE	n/a
Dividend	1.17 (4.66%)
Ex-Dividend Date	Sep 29, 2025

Volume	100
Average Volume	326
Open	25.00
Previous Close	24.97
Day's Range	25.00 - 25.20
52-Week Range	22.45 - 28.29
Beta	n/a
RSI	60.42
Earnings Date	Jan 29, 2026

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY